Biomarker strategy cuts unnecessary antifungal use in ICU without raising death risk

NCT ID NCT03538912

Completed Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated May 24, 2026 · Updated 1 time

Summary

This study looked at 192 critically ill patients who were given antifungal drugs for a suspected fungal infection. Researchers wanted to see if using special fungal biomarkers could allow doctors to safely stop the drugs earlier than usual. The goal was to reduce unnecessary medication while making sure it did not increase the risk of death by day 28.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE CANDIDIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CH ARRAS

Arras, France
CH Dunkerque

Dunkirk, France
CH Roubaix

Roubaix, France
CH de DOUAI

Douai, France
CHU de Rouen

Rouen, France
Centre Hospitalier Dr Schaffner

Lens, France
Centre hospitalier de valenciennes

Valenciennes, France
Ch Dr.Schaffner de Lens

Lens, France
Ch Tourcoing

Tourcoing, France
Hôpital Roger Salengro, CHU

Lille, France

Conditions

Explore the condition pages connected to this study.

INVASIVE CANDIDIASIS